Coral Drugs Pvt. Ltd. is pleased to announce that the U.S. FDA has completed a Good Manufacturing Practices (GMP) inspection of its manufacturing facility at Murthal, Sonepat conducted from April 2, 2025 to April 8, 2025. The Company has subsequently received the Establishment Inspection Report (EIR) from the agency, signifying the closure of the inspection process.

Coral Drugs Pvt. Ltd. continues to reinforce its compliance framework and views each inspection as an opportunity to further strengthen our systems and dedication to serving our clients and partners.

Coral Drugs Pvt. Ltd.

For any queries, please email us at contact@coraldrugs.com

‍